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The hereditary spastic paraplegias (HSPs) are genetic motor neuron diseases
characterized by progressive degeneration of corticospinal tract axons. Mutations in
SPAST, encoding the microtubule-severing ATPase spastin, are the most common
causes of HSP. The broad SPAST mutational spectrum indicates a haploinsufficiency
pathogenic mechanism in most cases. Most missense mutations cluster in the ATPase
domain, where they disrupt the protein’s ability to sever microtubules. However, several
putative missense mutations in the protein’s microtubule interacting and trafficking (MIT)
domain have also been described, but the pathogenicity of these mutations has not
been verified with functional studies. Spastin promotes endosomal tubule fission, and
defects in this lead to lysosomal enzyme mistrafficking and downstream lysosomal
abnormalities. We investigated the function of three disease-associated spastin MIT
mutants and found that none was able to promote normal endosomal tubule fission,
lysosomal enzyme receptor trafficking, or lysosomal morphology. One of the mutations
affected recruitment of spastin to endosomes, a property that requires the canonical
function of the MIT domain in binding endosomal sorting complex required for transport
(ESCRT)-III proteins. However, the other mutants did not affect spastin’s endosomal
recruitment, raising the possibility of pathologically important non-canonical roles for the
MIT domain. In conclusion, we demonstrate that spastin MIT mutants cause functional
abnormalities related to the pathogenesis of HSP. These mutations do not directly affect
spastin’s microtubule-severing capacity, and so we identify a new molecular pathological
mechanism by which spastin mutations may cause disease.
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INTRODUCTION
The hereditary spastic paraplegias (HSPs) are a group of inherited neurodegenerative disorders
characterized by spastic paralysis of the legs. This is caused by progressive degeneration of the
longest axons of the corticospinal tract, the main motor pathway that connects the brain to the
spinal cord (Harding, 1993; Reid, 1999; Fink, 2006). To date, more than 70 genes linked to HSP
have been identified (Hensiek et al., 2015). Mutations in the gene encoding spastin (SPAST/SPG4;
MIM:604277) are the most common cause of autosomal dominant uncomplicated “pure” HSP
(MIM:182601) in North America and northern Europe, accounting for ∼40% of cases (Hazan
et al., 1999; Blackstone et al., 2011). The wide spectrum of SPG4 mutations, including non-sense,
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frameshift, splice site, and missense mutations, as well as whole
exon and whole gene deletions, has led to a general consensus
that the disease has a haploinsufficiency pathological mechanism
in most cases, and this is supported by findings of reduced
expression of spastin protein in stem cell-derived neurons or
olfactory neurospheres from patients with a variety of spastin
mutational classes (Abrahamsen et al., 2013; Denton et al.,
2014; Havlicek et al., 2014; Rehbach et al., 2019). However, the
potential for dominant negative effects or even a gain of function
mechanism for some missense mutations has also been raised
(Hazan et al., 1999; Fonknechten et al., 2000; Errico et al., 2002;
Solowska et al., 2010, 2017).
Spastin is a microtubule-severing ATPase that uses energy
from ATP hydrolysis to sever microtubules. In microtubule
severing, spastin’s ATPase domains associate to form a hexameric
ring structure with a central pore, within which basic residues
interact with the C-terminal acidic tail of tubulin (Errico et al.,
2002; White et al., 2007; Roll-Mecak and Vale, 2008). ATP
hydrolysis is then coupled to microtubule severing by a process
that is still not fully understood, but which by analogy with
structures of the related enzyme katanin may involve cycling
of the hexameric complex between an open spiral and closed
ring, so providing the power stroke for microtubule breakage
(Roll-Mecak and Vale, 2008; Zehr et al., 2017).
There are two major isoforms of the spastin protein, which
are both ubiquitously expressed; a full-length M1 isoform and
a shorter M87 isoform, generated by mechanisms involving a
combination of alternative translation start sites in the full-
length transcript and an alternative transcript encoding only the
M87 form (Figure 1A) (Claudiani et al., 2005). At steady state,
M87 spastin is mainly cytosolic, while M1-spastin predominantly
localizes to the endoplasmic reticulum (ER), where it interacts
with a number of other HSP proteins that are involved in ER
shaping, such as REEP1 and Atlastin-1 (Sanderson et al., 2006;
Connell et al., 2009; Park et al., 2010; Montenegro et al., 2012).
These two isoforms of spastin appear to act in concert to drive
efficient fission of tubules from the early sorting endosome,
specifically at sites of contact between the endosomal tubules and
the ER (Connell et al., 2009; Allison et al., 2013, 2017).
Defective endosomal tubule fission following depletion
of spastin results in the missorting of receptors that traffic
via this tubular-vesicular pathway, including the mannose
6-phosphate receptors (M6PRs) (Allison et al., 2013, 2017).
As these receptors are not properly sorted away from
early endosomes in cells lacking spastin, they remain in
the endosomal compartment and traffic through to the
LAMP1-positive endolysosomal degradative compartment.
M6PRs normally cycle between the endosome and Golgi;
upon reaching the trans-Golgi network (TGN), they capture
M6P-tagged lysosomal enzymes and mediate their traffic to
the endoso-lysosomal degradative compartment (Carlton
et al., 2004). Thus, in cells lacking spastin, deficiency of
M6PRs at the TGN causes mistrafficking of lysosomal
enzymes that should be delivered from the TGN to the
endolysosomal compartment (Allison et al., 2017). In turn,
this causes abnormal lysosome morphology and function,
characterized by increased lysosomal size, the accumulation of
dense membranous material within the lysosomes, increased
lysosomal acidity, and a slight reduction in lysosome numbers
(Allison et al., 2017; Newton et al., 2018). The morphological
abnormalities are found in lysosomes in the cell bodies
and axons of human neurons derived from spastin-HSP
patients via induced pluripotent stem cells (iPSCs) and in
mouse primary cortical neurons from a spastin-HSP mouse
model (Allison et al., 2017). The abnormal lysosomes
accumulate in axonal swellings and so are compelling
candidates to be involved in the pathogenesis of spastin-
HSP. Similar abnormal lysosomal morphologies have also
been observed in several other genetic subtypes of HSP,
and we have proposed that lysosomal dysfunction is a
final common disease pathway for many subtypes of HSP
(Renvoise et al., 2014; Hirst et al., 2015; Allison et al., 2017).
Spastin’s recruitment to endosomal membranes relies
upon the interaction of its microtubule interacting
and trafficking (MIT) domain with two non-canonical
members of the endosomal sorting complex required for
transport (ESCRT)-III, CHMP1B and IST1 (Reid et al.,
2005; Agromayor et al., 2009; Yang et al., 2009; Renvoise
et al., 2010). The MIT domain of spastin binds to MIT-
interaction motifs (MIMs) in the C-terminal ends of
CHMP1B and IST1. A functional MIT domain that is
able to interact with ESCRT-III is critical for the correct
regulation of endosomal tubule fission and downstream
trafficking pathways by spastin, as introduction of the
artificial F124D mutation into the MIT domain, which
abrogates ESCRT binding and endosomal recruitment, leads
to defective endosomal tubule fission, perturbed endosome-
to-Golgi M6PR traffic, and abnormal lysosomal morphology
(Yang et al., 2009; Allison et al., 2013, 2017).
Most missense mutations associated with spastin-HSP are in
the ATPase domain and affect spastin’s microtubule severing
ability in a number of different ways; for example, they may
block ATP binding or hydrolysis, preventing hexamerization,
or disrupt the interaction between the ATPase domain and
tubulin, thereby rendering the ATPase domain non-functional
(White et al., 2007; Roll-Mecak and Vale, 2008). However,
several families with sequence changes in the region encoding
the MIT domain have also been described, although the
pathogenicity or mechanism of action of such putative mutations
has not been verified (Patrono et al., 2002; Crippa et al.,
2006; Rudenskaia et al., 2010). In this study, we investigate
the effects of several MIT domain mutants upon functions
of spastin. We show that these mutations are unable to
correctly regulate endosomal tubule fission, M6PR traffic, or
lysosomal morphology. One of the mutations studied affected
the canonical function of the MIT domain in recruitment of
spastin to endosomes. However, two other mutations did not
affect endosomal recruitment of spastin, indicating that non-
canonical functions of the MIT domain are also important
in driving endosomal tubule fission. Thus, we demonstrate
that MIT mutants cause cellular abnormalities related to
the pathogenesis of HSP via a novel mechanism that does
not directly involve disruption of the protein’s microtubule-
severing activity.
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FIGURE 1 | Disease-associated spastin MIT mutants cannot support normal endosomal tubule fission. (A) Schematic diagram of spastin’s domain structure,
annotated with the position of artificial (above) and disease-associated (below) mutants used in this study. HR, hydrophobic region; MIT, MIT domain; MTB,
microtubule binding domain; AAA, ATPase domain. (B–F) Wild-type HeLa cells or cells expressing the siRNA-resistant spastin constructs indicated were subjected to
(Continued)
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FIGURE 1 | mock transfection or siRNA knockdown (KD) of endogenous spastin, then fixed and labeled for endogenous SNX1. Insets show higher magnification
views of the boxed areas. Scale bar = 10µm. (G) The percentage of cells with the longest SNX1 tubule >2µm was counted (n = 100 cells per condition). Mean and
SEM are shown for three biological repeats. P-values were calculated using one-way ANOVA with Bonferroni’s post hoc multiple comparison test. In addition to the
p-values shown, the M87-wild-type KD value was significantly different from all other KD values, with a significance of at least p < 0.05. (H) Depletion of spastin and
expression of siRNA resistant constructs was confirmed by Western blotting with the antibodies indicated. GAPDH labeling is shown to verify equal sample loading.
METHODS
Patient
Informed written consent was obtained to publish anonymized
clinical and molecular genetic details from a patient with HSP
who attended the East Anglian Regional Genetics Service. The
participant also gave written informed consent to participate in
the Molecular Pathology of Human Genetic Disease study, for
which ethical approval was granted by the South Birmingham
and East of England Cambridgeshire research ethics committees.
Antibodies
Rabbit polyclonal anti-spastin (86–340) (raised against a
glutathione S-transferase fusion protein that incorporated
residues 86–340 of M1-spastin) antibodies were produced as
previously described (Connell et al., 2009). Mouse monoclonal
α-tubulin (DM1A) and peroxidase-conjugated secondary
antibodies for Western blotting were obtained from Sigma-
Aldrich; mouse monoclonal anti-myc (4A6) from EMD
Millipore; mouse monoclonal anti-SNX1 (611482) from BD
transduction laboratories; rabbit polyclonal anti-GFP (ab6556)
and mouse monoclonal anti-M6PR (ab2733) from Abcam;
mouse monoclonal anti-LAMP1 (H4A3) from Santa Cruz
Biotechnology, Inc.; rabbit polyclonal anti-GAPDH (2118)
from Cell Signaling Technology; and Alexa Fluor 488– and
568–labeled secondary antibodies for immunofluorescence from
Molecular Probes.
Constructs
pLXIN-myc-Spastin constructs were generated as previously
described (Allison et al., 2013). In brief, M87- or M1-spastin
was cloned into the pIRESneo2 vector (NheI–BamHI; Takara
Bio Inc.) followed by insertion of a myc tag (EcoRV–NheI),
and then myc-spastin was further cloned into the pLXIN vector
(SalI–BamHI; Takara Bio Inc.). Constructs weremade resistant to
spastin siRNA1 and three by introducing twomutations into each
of the relevant sequences by site-directed mutagenesis. Mutant
versions of pLXIN-myc-M87-spastin were then generated by site-
directed mutagenesis. The GFP-VPS4-E235Q construct was a gift
from P. Whitley (University of Bath, Bath, England, UK).
Generation of Stable Cell Lines
Stable cell lines were generated by retroviral transduction of
HeLa cells using the spastin pLXIN constructs described above,
according to previous methods (Allison et al., 2013).
Cell Culture and Transfection
HeLa cells were maintained as previously described (Connell
et al., 2009). HeLa cells stably expressing spastin constructs
were additionally cultured in the presence of 500µg/ml
Geneticin/G418 (Invitrogen). This selected for cells expressing
the constructs that contain a gentamycin resistance cassette.
In DNA transfections, cells were transfected using Effectene
Transfection Reagent (Qiagen) following the manufacturer’s
protocol and typically incubated with transfection reagents for
24 h. For siRNA transfection, cells were transfected with the
relevant siRNAs, using Oligofectamine transfection reagent
(Invitrogen), according to a protocol modified fromMotley et al.
(2003). In brief, cells were plated into one well of a six-well plate
and transfected after 24 h. Cells were harvested 48–96 h later. The
efficiency of siRNA knockdown was verified by immunoblotting
cell lysates or by immunofluorescent microscopy of fixed cells,
with an antibody against the relevant protein. The following





Cells were fixed at room temperature (RT) in 3.8% (vol/vol)
formaldehyde in phosphate buffered saline (PBS) and
permeabilized in PBS containing 0.1% (vol/vol) saponin
(Sigma-Aldrich) or 0.1% (vol/vol) Triton X-100 (Sigma-
Aldrich). Coverslips were labeled with primary and secondary
antibodies as previously described (Connell et al., 2009). Slides
were analyzed with an LSM880 confocal microscope (100×
NA 1.40 oil immersion objective, 37◦C), LSM780 confocal
microscope (63× NA 1.40 oil immersion objective, 37◦C), or
AxioImager Z2 Motorized Upright Microscope (63× NA 1.40
oil immersion objective, RT, Axiocam 506; ZEISS), all with ZEN
analysis software (ZEISS). Images were subsequently processed
using ImageJ, Adobe Photoshop, Adobe Illustrator, and ZEN
analysis software. Co-localization of proteins was quantified
using Volocity (PerkinElmer).
Endosomal Tubule Counts on Fixed Cells
Cells were processed for immunofluorescence microscopy and
imaged with an AxioImager Motorized Upright Microscope
under a 63×/1.4-NA oil immersion objective as described earlier.
Tubulation was quantified as described previously (Allison et al.,
2017). Briefly, images of typically 100 cells per experimental
condition were randomized and scored blind for the presence
of tubules longer than 2µm. The percentage of cells with such
tubules was then calculated.
Lysosome Quantification
The percentage of cells with large lysosomes was determined as
described previously (Allison et al., 2017); fixed cells labeled with
LAMP1were processed for immunofluorescencemicroscopy and
imaged with an AxioImager Motorized Upright Microscope. At
least 100 cells were recorded per experimental condition. Images
Frontiers in Neuroscience | www.frontiersin.org 4 November 2019 | Volume 13 | Article 1179
Allison et al. Spastin MIT Mutants and Paraplegia
were randomized, and the largest lysosome per cell was measured
using ZEN analysis software.
Electron Microscopy
HeLa cells were grown on plastic dishes and fixed with 2% PFA,
2.5% glutaraldehyde, and 0.1M cacodylate buffer, pH 7.2, before
being scraped and spun into a pellet. All samples were postfixed
with 1% osmium tetroxide:1.5% potassium ferricyanide before
being incubated with 1% tannic acid to enhance contrast. Cells
were dehydrated using increasing percentages of ethanol before
being embedded onto EPON stubs or beam capsules. Resin was
cured overnight at 65◦C, and coverslips were removed using a
heat-block (plastic) or repetitive freeze-thaw cycles with liquid
nitrogen (glass). Ultrathin (50–70-nm) conventional sections
were cut using a diamond knife mounted to a Reichart ultracut
S ultramicrotome. Sections were collected onto copper grids
stained using lead citrate. Sections were viewed on a FEI Tecnai
transmission electron microscope at a working voltage of 80 kV.
Yeast Two Hybrid Assay
Yeast two hybrid (Y2H) assays were carried out using the
Clontech Matchmaker system as previously described (Harbour
et al., 2010). Residues 110–199 of the spastin MIT domain (WT,
F124D, E112K, R115C, V162I, N184T, or L195V), full-length
IST1 or CHMP1B, were cloned into both pGBT9 (bait) and
pGAD424 (prey), generating fusions with the GAL4 binding
protein and GAL4 activation protein, respectively. The HF7c
strain was used as the reporter strain with growth on plates
lacking histidine (–His) as the readout, indicating that an
interaction has occurred. Yeast transformations were carried out
as described in Reddy and Seaman (2001).
GST Pull-Down Assay
Residues 110–199 of the spastin MIT domain (WT, F124D,
E112K, R115C, V162I, N184T, or L195V) were cloned into the
BamHI-XhoI sites of pGEX-4T2 (GE Healthcare Life Sciences).
The MIM domains of IST1, residues 319–364, and the single
MIM of CHMP1B, residues 174–199, with the addition of a
myc and a 6His tag were cloned into the BamHI-NotI sites of
pGEX-6P-1 (GE Healthcare Life Sciences).
Protein was expressed in BL21(DE3)pLysS Escherichia coli
and subsequently purified on GST sepharose as described
in Collins et al. (2002). Spastin MIT domain proteins were
eluted in buffer containing 10mM glutathione (Collins et al.,
2002), whereas the GST tag was removed from IST1 and
CHMP1B MIMs by overnight cleavage at 4◦C with Prescission
protease (GE Healthcare Life Sciences) as described in the
manufacturer’s protocol.
GST pull-down assays were carried out as follows: 2 nmole of
both bait (MIT domain) and prey (MIM) protein were bound
to 20 µl packed volume of glutathione sepharose beads in 1ml
pull-down buffer (PBS + 0.1% NP-40 + 1mM DTT) overnight
at 4◦C with rotation. Pull-downs were then washed three times
in ice-cold pull-down buffer and resuspended in 30 µl of 3x
protein sample buffer. Samples were then separated on an 18%
Tris-Tricine gel at 120V for 3 h in duplicate, half of each pull-
down Coomassie stained to assess total protein, and the other
TABLE 1 | Results of pathogenicity prediction programs for MIT domain sequence
changes identified in HSP patients.
Mutation SIFT prediction (score) PolyPhen prediction (score)
E112K Tolerated (0.74) Benign (0.017)
R115C Deleterious (0.02) Benign (0.251)
N184T Deleterious (0) Probably damaging (1)
L195V Deleterious (0) Possibly damaging (0.823)
half subject toWestern blotting and subsequent detection of prey
protein bands with anti-myc antibody (Millipore).
Statistical Analysis
Statistical analyses were performed by paired two-tailed t-tests or
one-way ANOVA with Bonferroni’s (when multiple treatments
were compared against each other) or Dunnett’s (when multiple
treatments were compared to a single control value) post hoc tests
for multiple comparisons tests, using GraphPad Prism version
5.01 for Windows, GraphPad Software, La Jolla California,
USA (www.graphpad.com).
RESULTS
Disease-Associated MIT Domain Mutants
Cannot Regulate Endosomal Tubulation
Three putative mutations in the MIT domain of spastin were
identified from the existing literature, E112K, N184T, and L195V
(Patrono et al., 2002; Crippa et al., 2006; Rudenskaia et al., 2010).
All were found in patients with pure HSP. A novel MIT domain
mutation was also identified in a patient attending the East
Anglian Medical Genetics Service, with a phenotype consistent
with pure HSP and no family history of spastic paraplegia, R115C
(SPAST c.343C>T). In each case, limited segregation data were
available, but the sequence changes each affect moderately to
highly evolutionarily conserved amino acids and are not present,
or in the case of R115C only present once, in the gnomAD
database of several hundred thousand alleles (Lek et al., 2016).
SIFT and Polyphen pathogenicity predictions for each variant,
generated via the Ensemble Variant Effect Predictor, are shown
in Table 1 (McLaren et al., 2016).
The MIT domain consists of three α helices that form an
anti-parallel up and down helix bundle fold, forming a MIM
binding region in between helices α1 and α3 (Yang et al.,
2009). R115C and E112K lie at the N-terminus of the MIT
domain, in the linker region adjoining helix α1, and L195V
is at the very C-terminus of helix α3. N184T lies within the
MIM binding region on α3 and is one of the residues involved
in MIT-CHMP1B MIM interaction (Figure 1A) (Yang et al.,
2009). We generated constructs encoding forms of spastin
containing each mutant. We began by confirming that each
retained the ability to sever microtubules, which we tested by
transiently expressing in HeLa cells and then assessing the
microtubule architecture by immunofluorescence microscopy
(Supplementary Figures 1A–F). Each of the mutants exhibited a
similar degree of microtubule depletion, which was comparable
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to that of wild-type spastin and distinct from the microtubule
bundling phenotype that has been observed in some missense
mutations that block ATP binding or hydrolysis (e.g., K388R;
Figure 1A; Supplementary Figure 1C) (Errico et al., 2002).
We next examined whether the patient MIT mutants affected
spastin’s role in endosomal tubule fission. Spastin requires the
ability to bind ESCRT-III and to hydrolyze ATP for this function,
as previous siRNA rescue experiments showed that forms of
spastin containing either the artificial F124D MIT mutation
(which blocks ESCRT-III interaction) or the disease-associated
K388R mutation (which blocks ATP hydrolysis), failed to rescue
the increased tubulation of sorting nexin 1 (SNX1; marker of a
subset of endosomal tubules) seen in cells lacking endogenous
spastin (Allison et al., 2013). We investigated the ability of
the disease-associated MIT mutants to promote endosomal
tubule fission using siRNA-rescue experiments with cells stably
expressing siRNA-resistant forms of M87-spastin harboring each
of the mutants (except the E112Kmutant, as repeated attempts to
generate a stable cell line failed). Stable expression of the patient
mutants did not affect the cellular microtubule architecture
(Supplementary Figures 1G–K). The increased SNX1 tubulation
phenotype seen in cells lacking endogenous spastin was rescued
by wild-type siRNA-resistant spastin but not by any of the patient
MIT mutant forms (Figures 1B–H). As the spastin-depleted cells
lack both endogenous M1- and M87-spastin, this effect of the
mutants cannot be via a dominant negative effect on wild-type
M1-spastin, as has been proposed as a mechanism for some
mutations that lie outside of the ATPase domain (Solowska et al.,
2010). We concluded that the amino acids affected by the patient
mutations are essential for spastin’s role in promoting endosomal
tubule fission.
Mutations in Spastin’s MIT Domain Disrupt
Endosome-To-Golgi Traffic
In cells depleted of spastin, defective endosomal tubule fission
causes failure of M6PR to sort away from the endosome,
resulting in its accumulation in a LAMP1-positive endolysosomal
compartment (Allison et al., 2017). This phenotype can be
rescued by wild-type spastin but not by forms unable to bind
ESCRT-III or hydrolye ATP (Allison et al., 2017). We examined
whether the disease-associated MIT mutants were able to rescue
this mislocalization of M6PR. Following siRNA-mediated spastin
depletion in wild-type HeLa cells, we observed a significant
increase in the co-localization of LAMP1 and M6PR, which
as expected was rescued by expression of wild-type myc-
M87 spastin (Figures 2A–D,K). However, none of the MIT
mutant forms rescued this phenotype (Figures 2E–K). Disease-
associated mutations in spastin’s MIT domain are therefore
unable to support normal sorting of M6PR from the endosome
to the Golgi, consistent with their inability to drive efficient
endosomal tubule fission.
Mutations in Spastin’s MIT Domain Lead to
Abnormal Lysosome Morphology
The abnormal M6PR traffic seen in HeLa cells lacking
spastin causes abnormal lysosomal enzyme delivery,
resulting in the development of enlarged lysosomes (Allison
et al., 2017), associated with increased cellular abundance
and altered migration of LAMP1 on immunoblotting
(Supplementary Figure 2). We interrogated the ability of
the MITmutants to rescue the lysosomal enlargement phenotype
with siRNA-rescue experiments and found that lysosomal
enlargement was rescued by wild-type M87-spastin but not
by any of the MIT mutant forms (Figures 3A–F). Two of the
mutants, R115C and L195V, also had a significant dominant
negative effect on lysosomal size in cells not depleted for
endogenous spastin (Figures 3C,E,F).
Lysosomes in spastin-HSP cellular models have a
characteristic ultrastructure, including the development of
thick membrane whorls and dense honeycomb networks of
membrane. We investigated the effects of the MIT mutants on
lysosome ultrastructure. As expected, upon spastin depletion,
we observed lysosomes with the characteristic abnormal
appearances (Allison et al., 2017). This phenotype was rescued
by wild-type M87 spastin but not by any of the MIT mutants
(Figure 3G). The residues affected by the patient mutations
are therefore required for spastin’s role in maintaining correct
lysosome morphology.
Spastin MIT Domain Mutants Show
Differential Recruitment to Endosomes
We next sought to understand the mechanism by which the
MIT mutants might affect spastin’s function in endosomal
tubule fission. At steady state, M87-spastin is mostly cytosolic
and shows minimal association with endosomal markers. The
canonical role of the MIT domain is to recruit spastin to
endosomes via interactions with ESCRT-III, and this can
be reported by expression of a dominant negative form of
VPS4 (VPS4-E235Q). VPS4 normally acts to remove ESCRT-
III proteins from endosomes, while the dominant negative form
traps ESCRT-III proteins and associated proteins, including
spastin, on the endosomal membrane, so revealing transient
endosomal localizations (Stuchell-Brereton et al., 2007; Connell
et al., 2009; Allison et al., 2013). Interestingly, the patient
MIT mutants showed differential recruitment to GFP-VPS4-
E235Q endosomes. Spastin-R115C and spastin-L195V showed
no significant reduction in recruitment when compared to
wild-type M87 spastin, while spastin-N184T had significantly
reduced co-localization with GFP-VPS4-E235Q. As expected,
endosomal recruitment of the ATPase mutant K388R was not
reduced, while recruitment of the artificial F124D MIT domain
mutant was almost completely abolished (Figures 4A–G). These
experiments suggest that, at least for the N184T mutant,
altered endosomal recruitment may account for the inability
to rescue the tubulation phenotype. However, these data also
indicate that the L195V and R115C mutants likely affect tubule
fission by a mechanism independent of spastin’s ability to
recruit to endosomes.
Finally, we tested directly whether the MIT mutants affect
binding of the spastin MIT domain to IST1 or CHMP1B. We
first examined this by yeast two-hybrid, where as expected
the artificial F124D MIT mutant showed no interaction
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FIGURE 2 | Endosome to Golgi M6PR traffic is disrupted by MIT domain mutations in spastin. (A–J) Wild-type HeLa cells or cells expressing the siRNA-resistant
spastin constructs indicated were subjected to mock transfection or siRNA-mediated KD of endogenous spastin, then processed for immunofluorescence
microscopy and labeled with antibodies to M6PR and the lysosomal marker LAMP1. Insets show higher magnification views of the boxed areas. Scale bar = 10µm.
(K) Co-localization between M6PR and LAMP1 was quantified by calculating the Pearson’s correlation coefficient for red and green pixels in each cell using Volocity
software (20 cells per condition quantified in each experiment). Mean and SEM are shown for n = 4 experiments. P-values were calculated using paired two-tailed
t-tests.
with CHMP1B or IST1 (Figures 5A–D). Unfortunately, auto-
activation of the N184T mutant in this assay meant that its
binding to the ESCRT proteins could not be assessed. However,
there was no clear reduction in binding of any of the other
patient MIT mutants, which exhibited interactions comparable
to the wild-type MIT domain and to a known benign spastin
polymorphism, V162I, which has an allele frequency of 2.22
× 10−3 in the general population (Lek et al., 2016). We next
examined binding using GST pull-downs, testing the ability of
purified wild-type and mutant spastin MIT domains to interact
with regions containing the MIMs of CHMP1B (amino acids
174–199) and IST1 (amino acids 319–364) (Agromayor et al.,
2009; Bajorek et al., 2009; Yang et al., 2009). As expected,
there was no binding between the MIT domain harboring the
Frontiers in Neuroscience | www.frontiersin.org 7 November 2019 | Volume 13 | Article 1179
Allison et al. Spastin MIT Mutants and Paraplegia
FIGURE 3 | Spastin MIT domain mutants cannot support normal lysosomal morphology. (A–E) Wild-type HeLa cells or cells expressing the siRNA-resistant spastin
constructs indicated were subjected to mock transfection or siRNA-mediated KD of endogenous spastin, then processed for immunofluorescence microscopy and
labeled for LAMP1. Insets show higher magnification views of the boxed areas. Scale bar = 10µm. (F) The diameter of the largest lysosome was measured in 100
(Continued)
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FIGURE 3 | cells per condition. The mean and SEM of the percentage of cells with largest lysosome >1.8µm is shown (n = 4 biological repeats). P-values were
calculated by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. In addition to the p-values shown, the M87 wild-type KD value was significantly
different from all other KD values with a significance of at least p < 0.01. (G) Wild-type HeLa cells or HeLa cells expressing the siRNA-resistant spastin constructs
indicated were subjected to mock transfection or siRNA-mediated KD of endogenous spastin. Electron micrographs of representative endolysosomal structures are
shown. Note the presence of highly abnormal structures in each of the cells expressing mutant spastin. Scale bar = 500 nm.
FIGURE 4 | MIT mutant forms of spastin show differential recruitment to VPS4-E235Q endosomes. GFP-VPS4-E235Q was transiently transfected into cell lines stably
expressing myc-tagged wild-type spastin (A) or spastin mutants (B–F), and then cells were fixed and labeled with an anti-myc antibody. Insets show higher
magnification views of the boxed areas. (G) Co-localization between GFP-VPS4-E235Q and spastin proteins was estimated by calculating the Pearson’s correlation
coefficient for red and green pixels in each cell, using Volocity software (n = 4 experiments, 15 cells per condition quantified in each experiment). Mean and SEM are
shown, p-values vs. M87 wild-type spastin were calculated using one-way ANOVA with Dunnett’s multiple comparison posttest. Scale bar = 10µm.
F124D artificial mutant and the ESCRT MIMs (data not shown).
Furthermore, in this system interaction was abolished (in the case
of CHMP1B) or reduced (in the case of IST1) by introduction
of another artificial MIT mutant (F124A) that is known to
significantly diminish, but not completely inhibit, binding of
spastin’s MIT domain to CHMP1B (data not shown) (Yang et al.,
2009). In contrast, there was no appreciable difference between
the MIM-binding capacity of the wild-type spastin MIT, an
MIT containing the benign polymorphism V162I, or any of the
spastin MIT mutants, including N184T (Figures 6A,B). Thus,
the abnormal functional effects of the mutants do not appear to
be related to their capacity to bind CHMP1B or IST1.
DISCUSSION
In this study, we have shown that three patient-associated
missense changes in the MIT domain affect the function of
Frontiers in Neuroscience | www.frontiersin.org 9 November 2019 | Volume 13 | Article 1179
Allison et al. Spastin MIT Mutants and Paraplegia
FIGURE 5 | Yeast two-hybrid analysis of spastin MIT domain binding to CHMP1B and IST1. (A–D) Interactions between the combinations of MIT domain, CHMP1B,
and IST1 bait and prey vectors indicated in each panel. In each case, the first column shows the growth of diploid colonies on media lacking leucine and tryptophan,
to select for the presence of both bait and prey vectors, while columns 2–6 show the growth of serial dilutions of diploid colonies on media lacking leucine, tryptophan,
and histidine, which also require the activation of the His reporter gene that occurs on interaction of bait and prey proteins. In (B,D), empty vector controls test for
auto-activation of by the MIT mutant proteins under investigation. Note that the N184T mutant causes auto-activation, and so binding results for this mutant were
uninterpretable.
spastin, rendering it unable to correctly regulate endosomal
tubule fission, with consequent effects on endosome-to-Golgi
trafficking of M6PRs and lysosomal morphology. The lysosomal
abnormalities are likely to be pathologically relevant as very
similar lysosomal morphologies are observed in neurons
from a spastin-HSP mouse model and from patient-derived
neurons, including in concentrations within pathological axonal
swellings (Allison et al., 2017). Considered together with the
absence, or in the case of R115C very low frequency, of these
mutations from general population databases, we conclude
that these missense changes are likely to be pathogenic. As
these mutations do not directly affect spastin’s microtubule-
severing capacity, coupling of these MIT mutations to lysosomal
dysfunction represents a new molecular pathological mechanism
by which spastin mutations may cause disease. A key challenge
now is to understand how lysosomal abnormality causes
axonopathy—numerous possibilities require exploration.
Functional lysosomes are required for autophagy andmitophagy,
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FIGURE 6 | Assessment of interactions between spastin MIT domains and MIM-regions of CHMP1B and IST1 by GST pull-down. Purified proteins consisting of GST
alone, GST fused to the wild-type spastin MIT domain, or to spastin MIT domains harboring the sequence changes indicated were used in in vitro GST pull-down
experiments vs. myc- and 6His-tagged fragments of CHMP1B (A) or IST1 (B) that incorporate the spastin-binding MIM regions. In each set of experiments, the upper
panels show Coomassie-stained gels, while the bottom panel shows corresponding anti-myc immunoblotting.
with defects in these processes linked to axonopathy (Ashrafi
et al., 2014; Gowrishankar et al., 2015; Xie et al., 2015). They are
also required for lipid metabolism, and altered lipid metabolism
appears sufficient to cause HSP (Boutry et al., 2019). Finally,
lysosomes are key sites of receptor degradation, and upregulated
bone morphogenetic protein signaling caused by defective
receptor degradation is implicated in HSP pathogenesis (Wang
et al., 2007; Tsang et al., 2009; Blackstone et al., 2011).
Of the mutations that we investigated in this study, only
the N184T change caused a large reduction (>50%) in the
endosomal recruitment of spastin, as compared to the wild-type
protein. Thus, in the case of this mutation, defects in endosomal
tubule fission, with consequent downstream defects on lysosome
function, are probably caused by insufficient endosomal spastin.
However, although structural studies of the binding of the MIT
domain to CHMP1B show that this mutation lies within the
MIM binding site and directly participates in MIM binding,
surprisingly, it did not appear to affect MIT-MIM binding
when assayed by GST pull-down (Yang et al., 2009). Spastin’s
recruitment to endosomes requires its MIT domain, but it is
not known whether CHMP1B and IST1 are the only endosomal
proteins involved in this recruitment. The simplest interpretation
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of our data is that another, perhaps novel, ESCRT-like protein
in addition to IST1 and CHMP1B participates in spastin’s
recruitment to endosomes, and that it is this binding that is
affected by the N184T alteration.
The other two mutants studied caused no reduction in
endosomal recruitment, consistent with their location outside
of the MIM-binding region of the spastin MIT domain. This
suggests that they are affecting a non-canonical function of the
MIT domain that is independent of ESCRT-III interaction and
invites the possibility that non-canonical functions of the MIT
domain are important for the correct function of spastin in
endosomal tubule fission. Although non-canonical functions of
the spastin MIT domain have not been elucidated, other MIT
domains have been proposed to have Ca2+ or phospholipid
binding properties (Iwaya et al., 2013). Interestingly, both of
these mutations showed dominant negative effects on lysosomal
size when stably expressed in HeLa cells. We suggest that in the
physiological situation in HSP patients, when these alleles are
expressed together with a wild-type allele, the mutant proteins
are likely incorporated into, and negatively affect the function of,
the spastin hexamer at the endosome.
In summary, by showing that MIT domain mutants do not
directly affect microtubule severing, but still have pathologically
relevant functional effects, we have identified a novel molecular
pathological mechanism by which alteration of spastin may cause
HSP. Our work hints at the existence of novel factors that
may determine recruitment of spastin to endosomes, as well as
indicating that interference with non-canonical functions of the
MIT domain may cause the disease.
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Supplementary Figure 1 | Spastin’s microtubule severing activity is unaffected
by MIT mutants. (A–F) Wild-type Hela cells were transiently transfected with the
myc-tagged M87-spastin constructs indicated. Cells were fixed and then
processed for immunofluorescence microscopy and labeled with antibodies to
myc and α-tubulin. Representative images showing the appearance of the
microtubule architecture following spastin overexpression are shown. Scale bar =
10µm. (G–K) Wild-type Hela cells or cells stably expressing the myc-tagged
M87-spastin constructs indicated were fixed, then processed for
immunofluorescence microscopy and labeled with (G) spastin and α-tubulin or
(H–K) myc and α-tubulin. Representative images showing the appearance of
microtubule cytoskeleton in each cell line, with and without endogenous spastin
depletion, are shown. Scale bars = 10µm.
Supplementary Figure 2 | Cells lacking spastin exhibit upregulation and altered
migration of LAMP1. (A) HeLa cells were mock-transfected or subjected to
spastin depletion by siRNA transfection, then immunoblotted with the antibodies
shown. Note increased abundance and altered LAMP1 migration in the
immunoblot from cells lacking spastin. Quantification of LAMP1 immunoblot band
intensity is shown in (B), n = 4, p-values generated by paired t-tests.
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